IONIS-JBI1-2.5

IONIS-JBI1-2.5 (also known as JNJ-73105191) is an orally delivered antisense oligonucleotide (ASO) developed through a collaboration between Ionis Pharmaceuticals and Janssen Biotech. It is designed to treat gastrointestinal immune disorders, specifically inflammatory bowel diseases (IBD) such as ulcerative colitis. The drug utilizes Ionis's antisense technology to target and reduce the expression of c-Rel, a member of the NF-κB family of transcription factors that plays a key role in the inflammatory response. By delivering the ASO orally, the treatment aims to provide local action within the gastrointestinal tract while minimizing systemic exposure, potentially offering a more targeted and safer therapeutic profile compared to systemic anti-inflammatory agents.